Literature DB >> 30409837

Quantitation of Lysosomal Trapping of Basic Lipophilic Compounds Using In Vitro Assays and In Silico Predictions Based on the Determination of the Full pH Profile of the Endo-/Lysosomal System in Rat Hepatocytes.

Maximilian V Schmitt1, Philip Lienau1, Gert Fricker1, Andreas Reichel2.   

Abstract

Lysosomal sequestration may affect the pharmacokinetics, efficacy, and safety of new basic lipophilic drug candidates potentially impacting their intracellular concentrations and tissue distribution. It may also be involved in drug-drug interactions, drug resistance, and phospholipidosis. However, currently there are no assays to evaluate the lysosomotropic behavior of compounds in a setting fully meeting the needs of drug discovery. We have, therefore, integrated a set of methods to reliably rank order, quantify, and calculate the extent of lysosomal sequestration in rat hepatocytes. An indirect fluorescence-based assay monitors the displacement of the fluorescence probe LysoTracker Red by test compounds. Using a lysosomal-specific evaluation algorithm allows one to generate IC50 values at lower than previously reported concentrations. The concentration range directly agrees with the concentration dependency of the lysosomal drug content itself directly quantified by liquid chromatography-tandem mass spectrometry and thus permits a quantitative link between the indirect and the direct trapping assay. Furthermore, we have determined the full pH profile and corresponding volume fractions of the endo-/lysosomal system in plated rat hepatocytes, enabling a more accurate in silico prediction of the extent of lysosomal trapping based only on pK a values as input, allowing early predictions even prior to chemical synthesis. The concentration dependency-i.e., the saturability of the trapping-can then be determined by the IC50 values generated in vitro. Thereby, a more quantitative assessment of the susceptibility of basic lipophilic compounds for lysosomal trapping is possible.
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30409837     DOI: 10.1124/dmd.118.084541

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients.

Authors:  Eveline Annette van de Stadt; Maqsood Yaqub; Robert C Schuit; Imke H Bartelink; Anke F Leeuwerik; Lothar A Schwarte; Adrianus J de Langen; Harry Hendrikse; Idris Bahce
Journal:  Diagnostics (Basel)       Date:  2022-04-01

2.  Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human.

Authors:  Xin Liu; William J Jusko
Journal:  J Pharmacol Exp Ther       Date:  2020-12-04       Impact factor: 4.030

3.  Differences in Cerebral Distribution between Imipramine and Paroxetine via Membrane Transporters at the Rat Blood-Brain Barrier.

Authors:  Shin-Ichi Akanuma; Myeongrae Han; Yuka Murayama; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Pharm Res       Date:  2022-02-02       Impact factor: 4.200

4.  Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations.

Authors:  Anne M Filppula; Rezvan Parvizi; André Mateus; Pawel Baranczewski; Per Artursson
Journal:  Sci Rep       Date:  2019-04-10       Impact factor: 4.379

5.  The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane.

Authors:  Michal Stark; Tomás F D Silva; Guy Levin; Miguel Machuqueiro; Yehuda G Assaraf
Journal:  Cells       Date:  2020-04-27       Impact factor: 6.600

6.  Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients.

Authors:  I H Bartelink; E A van de Stadt; A F Leeuwerik; V L J L Thijssen; J R I Hupsel; J F van den Nieuwendijk; I Bahce; M Yaqub; N H Hendrikse
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-27

7.  Lysosomal Biogenesis and Implications for Hydroxychloroquine Disposition.

Authors:  Keagan P Collins; Sandra Witta; Jonathan W Coy; Yi Pang; Daniel L Gustafson
Journal:  J Pharmacol Exp Ther       Date:  2020-11-10       Impact factor: 4.030

8.  Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2.

Authors:  Myasar Alkotaji
Journal:  Int J Antimicrob Agents       Date:  2020-10-10       Impact factor: 15.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.